Trial Profile

A phase III trial of evogliptin for type 2 diabetes

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 09 Oct 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Evogliptin (Primary)
Indications Type 2 diabetes mellitus
Focus Registrational; Therapeutic Use

Most Recent Events

09 Oct 2015 New trial record
02 Oct 2015 According to a Dong-A St media release, the South Korean MFDS (Ministry of Food and Drug Safety) has approved the NDA of SUGANON (DA-1229, Evogliptin 5mg tablet) for type 2 diabetes mellitus.
31 Dec 2014 According to the company Annual Report 2014, a New Drug Application was filed in 2015 for evogliptin to the South Korean MFDS (Ministry of Food and Drug Safety).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com